Forest Laboratories, Rotta Research Laboratorium S.p.A. deal

Rotta granted FRX U.S. marketing and development rights to dexloxiglumide, a cholecytokinin type A (CCKA) receptor antagonist, to treat irritable bowel syndrome. Dexloxiglumide increases gastric empt...